logo
Twitter
Discord
Email
logo
Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

NASDAQ•SNDX
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2016-03-02
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Contact Information
35 Gatehouse Drive, Building D Floor 3, Waltham, MA, 02451, United States
781-419-1400
www.syndax.com
Market Cap
$1.77B
P/E (TTM)
-5.8
40.1
Dividend Yield
--
52W High
$22.73
52W Low
$8.58
52W Range
84%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$45.87M+266.97%
4-Quarter Trend

EPS

-$0.70-28.57%
4-Quarter Trend

FCF

-$70.67M+13.39%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revuforj Product Revenue Nine months 2025 Product revenue reached $80.6M USD, driven by Revuforj launch post November 2024 approval.
Net Loss Reduction Nine months net loss narrowed to $217.4M USD, improving from $224.6M USD loss in prior comparable period.
New FDA Approval Trigger FDA approved Revuforj for R/R AML with NPM1 mutation, triggering $7.0M milestone payment in October 2025.
Cash and Investments Strong Total cash and investments stood at $456.1M USD as of September 30, 2025, supporting ongoing operations.

Risk Factors

High Accumulated Deficit Accumulated deficit reached $1.4B USD as of September 30, 2025; anticipates incurring significant losses next couple years.
High Operating Expenses Total operating expenses were $314.2M USD for nine months, driven by R&D and commercialization costs.
Clinical Trial Uncertainty Successful development remains highly uncertain; costs and timelines for future clinical trials are difficult to estimate accurately.
Competition Exposure Faces intense competition from established firms; market adoption depends on efficacy versus existing therapies like ruxolitinib.

Outlook

Pipeline Data Readouts Advancing multiple trials including EVOLVE-2 and SAVE; expects data readout for colorectal cancer trial in Q1 2026.
Future Funding Strategy Expects to fund future needs via equity offerings, debt financings, and ongoing collaboration revenue streams.
Niktimvo IPF Trial Progress Enrollment ongoing for MAXPIRE trial evaluating axatilimab for IPF; topline data anticipated in second half of 2026.

Peer Comparison

Revenue (TTM)

Syndax Pharmaceuticals, Inc.SNDX
$111.55M
+574.6%
Wave Life Sciences Ltd.WVE
$109.23M
+103.7%
Immatics N.V.IMTX
$93.54M
-26.7%

Gross Margin (Latest Quarter)

Immatics N.V.IMTX
100.0%
+0.0pp
Atai Life Sciences N.V.ATAI
100.0%
+0.0pp
Syndax Pharmaceuticals, Inc.SNDX
95.4%
-4.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$5.94B-22.2-66.9%0.1%
WVE$2.33B-19.1-72.9%76.4%
SYRE$1.90B-16.5-31.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
81.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 2, 2026
|
EPS:-$0.66
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 3, 2025|
    Revenue: $45.87M+267.0%
    |
    EPS: $-0.70-28.6%
    Meet

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $37.96M+984.5%
    |
    EPS: $-0.83+3.8%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 5, 2025|
    Revenue: $20.04M+0.0%
    |
    EPS: $-0.99+16.5%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $23.68M+0.0%
    |
    EPS: $-3.73-25.2%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $12.50M+0.0%
    |
    EPS: $-0.98+34.2%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $3.50M+0.0%
    |
    EPS: $-0.80+25.0%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.85+63.5%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 27, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.98-25.7%
    N/A